Eli Lilly’s big-selling insulin, Humalog, faces cut-price competition after the US regulator approved a biosimilar from Sanofi. Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 ...

Japan's health ministry has started considering ways to promote the use of follow-on products of very expensive original biological drugs. Options include increasing out-of-pocket costs of patients wh ...

Lifecore Biomedical and PolyPeptide Laboratories have linked to deliver an end-to-end peptide manufacturing solution for US ...

Novo Nordisk’s bid to provide a once-weekly basal insulin product for people with diabetes, reducing the number of injections needed, has hit a major hurdle in the US. The FDA sent the Danish ...